Measures of effectiveness in patients participating in postmarketing surveillance of etanercept in Japan.
| Effectiveness Measure, mean (SD) | Period After Treatment Initiation, weeks | ||
|---|---|---|---|
| Baseline | 4* | 24* | |
| DAS28 score | 6.0 (1.2) | 4.4 (1.3) | 3.9 (1.3) |
| n | 4643 | 2511 | 4248 |
| No. tender joints | 9.9 (7.1) | 4.5 (5.1) | 3.3 (4.4) |
| n | 6425 | 4010 | 6229 |
| No. swollen joints | 9.1 (6.3) | 4.3 (4.5) | 3.0 (3.7) |
| n | 6425 | 4009 | 6227 |
| Visual analog scale score, mm | 60.9 (22.4) | 37.2 (22.6) | 31.3 (22.5) |
| n | 5876 | 3420 | 5464 |
| ESR, mm/h | 61.1 (33.2) | 39.3 (28.1) | 37.1 (28.3) |
| n | 5059 | 3024 | 4923 |
| CRP, mg/dl | 3.8 (3.4) | 1.4 (2.1) | 1.3 (2.2) |
| n | 6399 | 4221 | 6427 |
| Duration of morning stiffness, min | 111.5 (181.7) | 44.3 (114.4) | 31.0 (90.3) |
| n | 5797 | 3169 | 4988 |
↵CRP: C-reactive protein; DAS: Disease Activity Score; ESR: erythrocyte sedimentation rate. * All different compared to baseline, p < 0.001.